Prognosis
Controversial ALS Drug From Amylyx Gets Rare Second FDA Meeting
- Panel votes 7-2 to support approval of the treatment
- Company’s drug was narrowly rejected by FDA advisers in March
This article is for subscribers only.
Amylyx Pharmaceuticals Inc. shares climbed after its controversial treatment for amyotrophic lateral sclerosis won the support of a panel of US regulatory advisers, putting the product on track for likely clearance.
During a rare second panel meeting on Wednesday, the Food and Drug Administration’s peripheral and central nervous system drugs advisory committee voted 7-2 to back approval of the treatment. The stock gained as much as 83% at the New York market open, the most since the biotech began selling shares in January.